Related Experiment Video
Updated: Oct 2, 2025

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple
Ettore Dolcetti1, Antonio Bruno1, Federica Azzolini1
1Neurology Unit, IRCSS Neuromed, 86077 Pozzilli, Italy.
Abstract:
The clinical course of multiple sclerosis (MS) is critically influenced by the interplay between inflammatory and neurodegenerative processes. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism (rs6265), one of the most studied single-nucleotide polymorphisms (SNPs), influences brain functioning and neurodegenerative processes in healthy individuals and in several neuropsychiatric diseases. However, the role of this polymorphism in MS is still controversial. In 218 relapsing-remitting (RR)-MS patients, we explored, at the time of diagnosis, the associations between the Val66Met polymorphism, clinical characteristics, and the cerebrospinal fluid (CSF) levels of a large set of pro-inflammatory and anti-inflammatory molecules. In addition, associations between Val66Met and structural MRI measures were assessed. We identified an association between the presence of Met and a combination of cytokines, identified by principal component analysis (PCA), including the pro-inflammatory molecules MCP-1, IL-8, TNF, Eotaxin, and MIP-1b. No significant associations emerged with clinical characteristics. Analysis of MRI measures evidenced reduced cortical thickness at the time of diagnosis in patients with Val66Met. We report for the first time an association between the Val66Met polymorphism and central inflammation in MS patients at the time of diagnosis. The role of this polymorphism in both inflammatory and neurodegenerative processes may explain its complex influence on the MS course.
Insights
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is linked to central inflammation and reduced cortical thickness in early multiple sclerosis (MS) patients. This finding offers new insights into MS pathogenesis.
Area of Science:
- Neuroscience
- Genetics
- Immunology
Background:
- Multiple sclerosis (MS) pathogenesis involves inflammation and neurodegeneration.
- The BDNF Val66Met polymorphism (rs6265) affects brain function but its role in MS is debated.
- Understanding genetic influences on MS is crucial for targeted therapies.
Purpose of the Study:
- To investigate the association of the BDNF Val66Met polymorphism with clinical, inflammatory, and structural MRI features in early relapsing-remitting MS (RR-MS).
- To explore the link between the Val66Met polymorphism and central nervous system inflammation markers.
Main Methods:
- Genotyping of the BDNF Val66Met polymorphism in 218 RR-MS patients at diagnosis.
- Analysis of cerebrospinal fluid (CSF) cytokines using principal component analysis (PCA).
- Assessment of structural MRI measures, including cortical thickness.
Main Results:
- The Met allele of the BDNF Val66Met polymorphism was associated with specific pro-inflammatory cytokines (MCP-1, IL-8, TNF, Eotaxin, MIP-1b) in CSF.
- No significant associations were found between the polymorphism and clinical characteristics of RR-MS.
- Patients with the Val66Met polymorphism showed reduced cortical thickness at diagnosis.
Conclusions:
- This study provides the first evidence linking the BDNF Val66Met polymorphism to central inflammation in newly diagnosed MS patients.
- The Val66Met polymorphism may influence both inflammatory and neurodegenerative pathways in MS.
- These findings highlight the potential role of BDNF genetics in MS pathophysiology and course.
Related Concept Videos
Neural Regulation
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

